AAM
FPRX

Aureus Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Aureus Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-31,600
Closed -$486K – 176
2015
Q3 		$486K Sell
31,600
-207,590
-87% -$4.46M 0.12% 85
2015
Q2 		$5.94M Buy
239,190
+97,320
+69% +$2.17M 1.25% 37
2015
Q1 		$3.24M Buy
+141,870
New +$3.58M 0.75% 44

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Aureus Asset Management's FPRX Position: Q4 2015 in Review

Aureus Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2015, closing a stake of 31,600 shares — an estimated $486K sold.

Aureus Asset Management first reported a position in FPRX in Q1 2015 and held it in 3 quarters. The position peaked at $5.94M in Q2 2015. 128 funds tracked by Wall St. Rank hold FPRX as of Q4 2015.

  • Aureus Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Aureus Asset Management sold 31,600 Five Prime Therapeutics, Inc. shares in Q4 2015, an estimated $486K.
  • Aureus Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Aureus Asset Management's Five Prime Therapeutics, Inc. position peaked at $5.94M in Q2 2015.
  • 128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2015.

Based on Aureus Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.